Mounjaro rose 65% to $10.7 billion and Zepbound grew 49%, but Lilly says realized prices fell 15% worldwide, partly from Mounjaro's lower price in China.
Recap by typeshit. Full story at Value The Markets.
Obesity specialist Dr. Alexandra Sowa says long-term use makes cost the flashpoint, as insurers and employers scale back coverage and Medicare benefits face a 2027 question.
With 30% of covering employers weighing cuts, Wegovy and Zepbound users should check their plans now. Includes current self-pay prices and tips for appeals.
Endpoints News
Endpoints News reports Lilly's direct-to-patient sales model, built on Americans paying hundreds a month, is now becoming part of its plans overseas.
West Pharmaceutical shares are up about 20% since CNBC flagged the valuation in August, and the latest earnings give it reasons to expect further gains.
Highlights include REDEFINE 9 results on low-dose CagriSema, full STEP Young data in kids aged 6 to under 12, and real-world Wegovy pill outcomes.
17:15
Sandy Gibson shares a personal update two months into taking tirzepatide and weighs whether it is doing its job.
Loading…